Chromatin remodeling factor LSH affects fumarate hydratase as a cancer driver

Area of Science:

• Oncology
• Epigenetics
• Cancer Metabolism

Background:

• Cancer progression involves complex interplay between metabolism and epigenetics.
• The role of lymphocyte-specific helicase (LSH) in nasopharyngeal carcinoma (NPC) and its metabolic links are not fully understood.
• Epstein-Barr virus (EBV) infection is associated with NPC development.

Purpose of the Study:

• To investigate the physiological role of LSH in NPC progression.
• To elucidate the relationship between LSH, cancer metabolism, and the tricarboxylic acid (TCA) cycle in NPC.
• To explore the epigenetic mechanisms driving NPC progression.

Main Methods:

• Analysis of LSH expression in NPC tissues.
• Investigation of LSH's interaction with fumarate hydratase (FH) and euchromatic histone-lysine N-methyltransferase 2 (EHMT2/G9a).
• Assessment of FH depletion effects on epithelial-mesenchymal transition (EMT).
• Evaluation of LSH's role in regulating TCA cycle intermediates and activation by inhibitor of nuclear factor kappa-B kinase alpha (IKKα).

Main Results:

• LSH is overexpressed in NPC and correlates with EBV infection.
• LSH, with EHMT2, directly suppresses FH activity, a key TCA cycle enzyme.
• FH depletion induces EMT, a critical process in cancer progression.
• LSH regulates TCA cycle intermediates via IKKα activation, promoting cancer progression and EMT.

Conclusions:

• LSH is a critical driver of NPC progression through epigenetic suppression of FH and modulation of TCA cycle intermediates.
• The LSH-FH axis and its impact on EMT represent a potential therapeutic target for NPC.
• Understanding the interplay between LSH, epigenetics, and cancer metabolism offers novel strategies for NPC treatment.